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Pharmaceutical Use on Shuttle 
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Medication Usage 
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Human Exploration Research Analog 
(HERA)
The Human Exploration 
Research Analog is a two-story, 
four-port habitat unit. It is 
cylindrical with a vertical axis, 
and connects to a simulated 
airlock and hygiene module 
Duration:  4-60 days 
Room Temperature:  72° F. (+/- 5 
degrees)
Light/Dark Cycle: Lights on 0600, 
lights out 2130, 7 days per week, 
no napping is permitted
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Health and Environmental Sciences Institute
Mission: Engage scientists from academia, government, 
industry, research institutes, and NGOs to identify and resolve 
global health and environmental issues.
NASA Human Health and Performance Center (NHHPC) 
is a virtual center that brings organizations together to 
advance human health and performance innovations for 
life in space and on Earth by sharing best practices and 






Wotring                    JSC NASA Pharmacology      11 December 2014
Pharmacokinetics‐
Does the spaceflight environment alter PK? 
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PK Evidence: Flight studies


















for clearance.   Saivin et al., 1995





Kates et al., 1980
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Lack of normal circadian cues probably 
contributes to sleep problems. 







almost 100,000) and lows of ~1 lux  (Dijk et al.,2001). 
This variability is not unlike the 15 min at 
10,000 lux followed by 60 min at <3 lux 
cyclical paradigm found to have similar 
phase resetting properties as the same 
total time period of 10,000 lux  (Rimmer et 
al.,2000).
Spaceflight lighting environment
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Methods …crew members assigned to Space Transportation System shuttle flights with in-flight
experiments between July 12, 2001, and July 21, 2011, or assigned to International Space Station
(ISS) expeditions between Sept 18, 2006, and March 16, 2011…wrist actigraphy, and subjective
sleep characteristics and hypnotic drug use via daily logs, in-flight and during Earth-based data-
collection intervals…
Findings We collected data from 64 astronauts on 80 space shuttle missions (26 flights,
1063 in-flight days) and 21 astronauts on 13 ISS missions (3248 in-flight days), with ground-
based data from all astronauts (4014 days). Crew members attempted and obtained significantly
less sleep per night as estimated by actigraphy during space shuttle missions (7·35 h [SD 0·47]
attempted, 5·96 h [0·56] obtained), in the 11 days before spaceflight (7·35 h [0·51], 6·04 h [0·72]),
and about 3 months before spaceflight (7·40 h [0·59], 6·29 h [0·67]) compared with the first
week post-mission (8·01 h [0·78], 6·74 h [0·91]; p<0·0001 for both measures). Crew
members on ISS missions obtained significantly less sleep during spaceflight (6·09 h [0·67]),
in the 11 days before spaceflight (5·86 h [0·94]), and during the 2-week interval scheduled about 3
months before spaceflight (6·41 h [SD 0·65]) compared with in the first week post-mission (6·95
h [1·04]; p<0·0001). 61 (78%) of 78 shuttle-mission crew members reported taking a dose of sleep-
promoting drug on 500 (52%) of 963 nights; 12 (75%) of 16 ISS crew members reported using
sleep-promoting drugs.
Interpretation Sleep deficiency in astronauts was prevalent not only during space shuttle and ISS
missions, but also throughout a 3 month preflight training interval. Despite chronic sleep
curtailment, use of sleep-promoting drugs was pervasive during spaceflight. Because chronic
sleep loss leads to performance decrements, our findings emphasise the need for
Prevalence of sleep deficiency and use of hypnotic drugs in 
astronauts before, during, and after spaceflight: an
observational study
Laura K Barger, Erin E Flynn-Evans, Alan Kubey, Lorcan Walsh, Joseph M Ronda,
Wei Wang, Kenneth P Wright Jr, Charles A Czeisler (Lancet Neurology 2014)




















































90 days before launch 11 days before launch In-flight 7 days after return to Earth 
 
Figure 1: Mean sleep duration before, during, and after shuttle missions 
Horizontal lines within  box plots show the median value for each interval  based on means for each participant; the 
25th and 75th percentiles are represented by the bottom and top of the box, respectively, and the 10th and 90th 
percentiles as error bars. The dots represent individual participants with means lower than the 10th or higher than 
the 90th  percentile. *Mean sleep duration was less during the two preflight periods and in-flight than in the 7-day 
post-flight interval (adjusted p<0·0001 for all three comparisons). 
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Sleep deprivation has 
cognitive effects 
The two images above show areas of the brain where blood flow decreases 
when a person is deprived of sleep for 24 hours, compared with when they 
are rested. Researchers suspect that reduced blood flow in such areas as 
the prefrontal cortex, located toward the front of the head (the top of each 
image), may be linked to deficits in concentration and other kinds of 
cognitive performance that are noted in people who have lost a lot of sleep. 
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Figure 1: Mean sleep duration before, during, and after shuttle missions 
Horizontal lines within  box plots show the median value for each interval  based on means for each participant; the 
25th and 75th percentiles are represented by the bottom and top of the box, respectively, and the 10th and 90th 
percentiles as error bars. The dots represent individual participants with means lower than the 10th or higher than 
the 90th  percentile. *Mean sleep duration was less during the two preflight periods and in-flight than in the 7-day 
post-flight interval (adjusted p<0·0001 for all three comparisons). 
Study will include measures of sleep and ultrasounds, in addition to  standard 
pharmacokinetic measures (circulating drug concentrations over time). 







Samples must be 
returned to Earth for 
analysis currently, but in 
the future, lab-on-a-chip 
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Because testosterone has effects on many 
tissues, its therapeutic use (to improve 
muscle mass) is linked to effects on 
reproductive organs, mood, behavior, blood 
lipids, other organs. 
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Selective androgen receptor 
modulators (SARMs)
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Pharmacological intervention sites for 
SAS 
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Not all antiemetics are effective 
against rotation‐induced illness
Levine et al., 2000
Self‐ratings of illness with 
ondansetron are no different than with placebo.
Ondansetron is the 5HT3 antagonist antiemetic that revolutionized cancer 
chemotherapy,  
N=12, double-blind, repeated measures, 1 week intervals, rotating drum stimulus. 
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Not all antiemetics are effective against 
wave‐induced illness










































data from Reid et al., 2000
N=16, double-blind, randomised, crossover design; stimulus 
was a rotating chair, subjects performed head movements 
during rotation; trials were stopped at subject report of Malaise
Neurokinin antagonists are ineffective 
against motion‐induced illness
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Reduction in severe SAS after 
introduction of PMZ
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General NASA info: http://www.nasa.gov
Human Research at NASA: http://humanresearch.jsc.nasa.gov/
NASA Research Grants http://nspires.nasaprs.com/external/
NSBRI  http://www.nsbri.org/
Bedrest Study Info: http://www.bedreststudy.com
Postdoctoral Opportunities  http://nasa.orau.org/postdoc/
Don Pettit’s Blog  http://blogs.airspacemag.com/pettit/
Ginger virginia.e.wotring@nasa.gov
Need more ? 
www.nasa.gov
